General Catalyst Commits $1B to David Beckham’s IM8 Supplement Brand

IM8 is being hailed as the fastest-growing premium supplement brand ever recorded, reaching approximately $17 million in monthly revenue

IM8, the supplement brand co-founded by former soccer pro David Beckham and Prenetics CEO Danny Yeung, has secured $1 billion in non-dilutive growth financing from General Catalyst.

The funding will accelerate customer acquisition across the brand’s 43-country footprint and comes as the supplement boom shows no signs of slowing.

IM8 reported approximately $17 million in preliminary, unaudited revenue in June 2026 and is projected to reach $300 million in annualized run-rate revenue by year-end 2026, with $400 million or more expected for full-year 2027.

IM8 debuted with two NSF Certified for Sport products at launch: Daily Ultimate Essentials, a 90-ingredient daily vitamin in powder form, and Daily Ultimate Longevity. 

The brand has attracted a slew of ambassadors and equity partners including Jay Shetty, NBA star Giannis Antetokounmpo and, most recently, Inter Miami CF, the Major League Soccer club Beckham co-owns with Jorge Mas and Jose Mas.

New product launches are on the roadmap, including IM8 Hydration and a premium gummies line. The company is also conducting two randomized controlled trials on gut health and longevity, aligning with its mission of creating products that are backed by science and likely to resonate with consumers who are demanding more than marketing claims.

“IM8 is a category-defining consumer health business, and the underlying cohort economics are among the strongest we’ve seen across the Customer Value Fund portfolio,” General Catalyst partner Adit Swarup said. “We believe this partnership can help position IM8 as one of the leading global consumer health brands of the coming decade.”